[Amended] Material event report (equity acquisition)

What happened

Equity and capital contribution securities acquisition decision in another corporation CXI Healthcare Technology Group Limited

Amendment report (notice) August 19, 2026

1. Disclosure document being amended: Material event report (decision on acquisition of equity and capital contribution securities in another corporation) 2. Original filing date of the disclosure document being amended: July 15, 2026 3. Amendment items:

Item: 5. Expected acquisition date, Reason: Amendment following completion of registration, Before: August 31, 2026, After: August 19, 2026 Item: 15. Other material matters relevant to investment judgment, (6), Reason: Amendment following completion of registration Before: "The above '5. Expected acquisition date' is based on the expected date of receipt of registration documents upon completion of the gratuitous transfer, and may change depending on the processing schedule of the relevant local authorities." After: "The above '5. Expected acquisition date' is the date on which the registration for the gratuitous transfer was completed."

Material event report / Matter subject to KRX reporting obligation To: Financial Services Commission / Korea Exchange July 15, 2026 Company name: CXI Healthcare Technology Group Limited CEO: LIN JIN SHENG Head office location: Third Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands Phone: 86-591-8803-1033 Website: http://cxihealthcare.com Preparer: (Title) Disclosure Officer (Name) LIN HANGHAN (Phone) 02-782-0560 (disclosure agent contact)

Decision on acquisition of equity and capital contribution securities in another corporation 1. Issuing company: Company name: Fujian Yongsheng Huoli Bioengineering Co., Ltd.; Nationality: China; Representative: CHEN ZHEN; Capital stock (KRW): 1,891,600,000; Relationship with company: subsidiary; Total shares issued: -; Main business: manufacture and sale of health supplements; Third-party placement new-share acquisition within the last 6 months: No 2. Acquisition details: Number of shares acquired: -; Acquisition amount (A) (KRW): 313,153,708,470; Total assets (B) (KRW): 494,176,463,326; (A/B) % of total assets: 63.37; Equity (C) (KRW): 491,642,280,374; (A/C) % of equity: 63.70 3. Shares held and equity ratio after acquisition: Shares held: -; Equity ratio (%): 100 4. Purpose of acquisition: Improving management and decision-making efficiency through restructuring of the governance structure 5. Expected acquisition date: August 19, 2026 6. Counterparty: Company name: Zhejiang Zhengsheng Health Science & Technology Group Co., Ltd.; Capital stock (KRW): 84,100,536,000; Main business: investment; Head office location: Fuzhou, Fujian, China; Relationship with company: subsidiary 7. Payment of transaction consideration: Gratuitous transfer, no transaction consideration 8. External valuation: Yes - Basis and reason: (1) Basis: appropriateness assessment under Article 161 of the Financial Investment Services and Capital Markets Act and Article 171 of its Enforcement Decree. (2) Reason: reference material for assessing the appropriateness of the asset transfer price, and attachment to the material event report. External valuation institution: Indeok Accounting Corporation External valuation period: May 1, 2026 to June 24, 2026 External valuation opinion: Using the discounted cash flow (DCF) method, the valuer assessed the value of the target company as of the valuation date at between a minimum of CNY 1,423,879 thousand and a maximum of CNY 2,008,006 thousand. As the transfer between the Company and the transferor is to be conducted gratuitously, the actual transaction is not within this assessed range. 9. Date of board resolution (decision date): July 15, 2026; attendance of independent (outside) directors*: attended -, absent -; attendance of auditor: attended 10. Whether this constitutes a backdoor listing: No; plans for a third-party placement capital increase, etc. within the next 6 months: No 11. Whether the issuing company meets the requirements for a backdoor listing: No 12. Subject to Fair Trade Commission reporting: Not applicable 13. Whether a put option or other agreement has been concluded: No; contract details: - * Independent director for listed companies, outside director for unlisted companies 14. Future plans for corporate restructuring: Before completion, the issuing company Fujian Yongsheng Huoli Bioengineering Co., Ltd. is a sub-subsidiary of the Company, 100%-owned by the Company's subsidiary Zhejiang Zhengsheng Health Science & Technology Group Co., Ltd. After completion, the Company will directly hold 100% of the issuing company, reclassifying it from sub-subsidiary to direct subsidiary, for governance restructuring and improved management/decision-making efficiency within the same consolidated group. 15. Other material matters relevant to investment judgment: (1) This transaction is a gratuitous intra-group transfer for governance restructuring and involves no cash inflow or outflow; the external valuation range and the transaction consideration accordingly do not coincide. (2) A Chinese limited liability company's registered capital is not divided into shares (no concept of share count or par value); shareholders hold an interest corresponding to actual paid-in capital, so this disclosure states no share count or par value. (3) "1. Capital stock of the issuing company" is based on the separate financial statements as of the most recent fiscal year end (June 2025), applying the KRW 189.16/CNY exchange rate published by Seoul Money Brokerage Services Ltd. as of June 30, 2025, to the issuing company's capital stock of CNY 10,000,000. (4) The Company's "total assets" and "equity" in "2. Acquisition details" are based on the consolidated financial statements as of the most recent fiscal year end, applying the KRW 189.16/CNY rate as of June 30, 2025, to the Company's total assets of CNY 2,612,478,660 and equity of CNY 2,599,081,626. (5) "2. Acquisition amount (KRW)" applies the KRW 219.93/CNY exchange rate published by Seoul Money Brokerage Services Ltd. as of the base date July 15, 2026, to the valuation amount of CNY 1,423,879,000. (6) "5. Expected acquisition date" is the date on which the registration for the gratuitous transfer was completed. (7) "6. Capital stock of the counterparty" is based on the most recent fiscal year end (June 2025), applying the KRW 189.16/CNY rate as of June 30, 2025, to the counterparty's capital stock of CNY 444,600,000. ※ Related disclosures: Not applicable.

[Summary financial status of the issuing company] (Unit: KRW million) Item | Total assets | Total liabilities | Total equity | Capital stock | Revenue | Net income | Audit opinion | External auditor Current year: 454,737 / 115,795 / 338,942 / 1,892 / 53,842 / 10,894 / - / - Prior year: 448,232 / 117,706 / 330,526 / 1,904 / 67,520 / 20,904 / - / - Year before that: 389,758 / 96,062 / 293,696 / 1,811 / 70,508 / 10,121 / - / - * Translated into KRW using period-end rates for balance-sheet items and average rates for income-statement items (Seoul Money Brokerage Services Ltd.). Note 1) Current year (2025): period-end rate KRW 189.16/CNY, average rate KRW 194.05/CNY. Note 2) Prior year (2024): period-end rate KRW 190.43/CNY, average rate KRW 184.17/CNY. Note 3) Year before that (2023): period-end rate KRW 181.05/CNY, average rate KRW 189.95/CNY. * Based on financial statements that have not been externally audited.

[Matters concerning the counterparty] 1. Basic information: Name: Zhejiang Zhengsheng Health Science & Technology Group Co., Ltd.; Nationality: China; Address: Fuzhou, Fujian, China; Occupation (business): Investment - Largest shareholder, CEO, representative executive officer and financial status: CEO SUN SHUANGYI; shares -; equity ratio - (Unit: KRW million) Most recent fiscal year 2025, settlement month June: Total assets 111,719; Capital stock 84,101; Total liabilities 12,589; Revenue 0; Total equity 99,130; Net income (loss) -2,632; External auditor -; Business suspension: No; Audit opinion -; Closure of business: No 2. Relationship with the issuing company or its largest shareholder/officers: Relationship between issuing company and counterparty: largest shareholder itself. Largest shareholder LIN JIN SHENG and CEO LIN JIN SHENG of the issuing company: relationship with counterparty -. 3. Transactions in the most recent 3 years (excluding ordinary transactions): Current year -; Prior year -; Year before that -